Pfizer launches Phase III trial for Lyme disease vaccine
Drug Discovery World
AUGUST 12, 2022
Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. April 2022.
Let's personalize your content